Cardiac arrest & resuscitation
Duration of Device-Based Fever Prevention after Cardiac Arrest
Primary resultResult — go to the resultHazard ratio 0.99 95% CI 0.77–1.26Authors' conclusion
Active device-based fever prevention for 36 or 72 hours after cardiac arrest did not result in significantly different percentages of patients dying or having severe disability or coma.
Study context
- Population
- Comatose patients resuscitated after OHCA of presumed cardiac cause
- Participants
- 393 vs 396
- Comparison
- Device-based fever prevention for 36 vs 72 hours
- 36-hourn = 393
- 72-hourn = 396reference
- Primary endpoint
- Composite of death from any cause or hospital discharge with Cerebral Performance Category 3 or 4 (severe cerebral disability or coma)
- Follow-up
- Within 90 days after randomization
Primary result
As reported in the abstract
90 days
Hazard ratio
0.99
95% CI 0.77–1.26
P = 0.70
Events by treatment group
36-hour vs 72-hour
HR 0.99 (95% CI 0.77–1.26); P = 0.70
Secondary outcomes
Mortality · 90 days
Median
| Outcome | 36-hour | 72-hour |
|---|---|---|
| Montreal Cognitive Assessment score (range 0 to 30, higher = better) · 3 months | 26 (IQR 24–29) | 27 (IQR 24–28) |
Safety
- No significant between-group difference in the incidence of adverse events
Original publication
Duration of Device-Based Fever Prevention after Cardiac Arrest. N Engl J Med. Published 6 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →